Teva Pharmaceuticals agreed to a patent litigation settlement with Novo Nordisk that would see the generic drugmaker wait until December 2023 to begin marketing its generic version of the type 2 diabetes drug Victoza (liraglutide).
Novo Nordisk filed a lawsuit in March 2017 after Teva submitted an ANDA application to the FDA seeking approval for a generic version of the drug. Novo Nordisk alleged that Teva was engaging in patent infringement.
The deal — which is subject to review by the Federal Trade Commission and the Department of Justice — awards Teva a license to launch a generic version of Victoza starting Dec. 22, 2023.
Teva could launch the generic sooner than the December date “under certain circumstances,” but it would be no earlier than March 22, 2023, unless the Victoza patents were no longer in effect or another generic version of the treatment hit the market, Novo Nordisk said.